Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration
Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration
Kodiak Sciences Inc ($KOD)
Will this trial show a positive result on best corrected visual acuity (BCVAOutcome measureBest-Corrected Visual Acuity (BCVA)Best-corrected visual acuity measures vision after correction with glasses or lenses. ETDRS letters are a standardized way to count vision gains or losses in ophthalmology trials.ClinicalTrials.gov outcome), Mean change in BCVA from Day 1 to Year 1, Week 48?
Paper Trading
Create account to trade- Primary Completion
- 8/1/26
- Study Completion
- 8/1/27
- Sponsor
- Ticker
- $KOD
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 675
- NCT
- NCT06556368
- Trial Description
- This Phase 3 trial tests tarcocimab tedromer and tabirafusp tedromer in wet AMD, measuring vision change at 48 weeks.